Article Sidebar

Submitted
12 January 2021
Accepted
12 January 2021
Published
30 September 2020
Download
PDF
Statistic
Read Counter : 613 Download : 463

Main Article Content

Abstract

Background: Longterm exposure to aminoglycoside such as kanamycin to cochlear cells is known to be associated with damage to outer hair cells in the organ Cortiand type 1 sensory hair cells in the vestibular organs which ultimately causes permanent damage to hair cells. Hair cell damage occurs from the basal cochlea (high frequency area) to the apex cochlea (low frequency area) and followed by damage from the auditory nerve. Evaluation of cochlear dysfunction on multidrug resistant tuberculosis (MDR TB) patients have been rarelyreported in the literature based on distortion product otoacoustic emission (DPOAE).Objectives: To prove cochlear dysfunction after kanamycin injection in MDR TB patient based on DPOAE examination of the overall frequencies and specific frequency.

Methods: An observational longitudinal analytic with pre and post design without control group conducted in the infection division of MDR TB Outpatients Pulmonology Department and Otorhinolaryngology Community division of ORL-HNS Department Dr. Soetomo general hospital Surabaya, within 3 months in 2018, 15 ear with the best baseline examination were taken by consecutive sampling and statistical analysis for cochlear dysfunction based on overall  frequency and specific frequency DPOAE examination using Mc Nemar test.

Results: Based on DPOAE examination of overall frequencies there was no cochlear dysfunction (p > 0.05) but a significant difference was found at frequency of 10,000 Hertz (Hz) (p = 0.002 ).

Conclusion:On ototoxicity monitoring there was no cochlear dysfunction after 4 weeks  Kanamycin injection but cochlear dysfunction occurs at a specific frequency of 10,000 Hz.

Keywords

cochlear dysfunction DPOAE kanamycin multi drug resistant tuberculosis

Article Details

License

Copyright (c) 2020 Folia Medica Indonesiana

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Brahmono, A., Purnami, N., & Surarso, B. (2020). Cochlear Dysfunction after Kanamycin Injection in Multidrug Resistant Tuberculosis Patients. Folia Medica Indonesiana, 56(3), 216–222. https://doi.org/10.20473/fmi.v56i3.24559
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Ribeiro L, Sousa C, Sousa A, Ferreira C, Duarte R, Almeida AFE, et al. Evaluation of hearing in patients with multiresistant tuberculosis. Acta Med Port. 2015; 28(1):87-91.
  2. Petersen L, Rogers C. Aminoglycoside induced hearing deficits - a review of cochlear ototoxicity. S Afr Fam Pract. 2015; 57(2):77-82.
  3. Rachana D, Shabnam S. Sensorineural hearing loss in patients with multidrug resistant tuberculosis: case studies. Acta Oto Laryngologica Case Reports. 2017; 2(1):96-102.
  4. Schlauch RS, Nelson P. Puretone evaluation. In : Katz J, Chasin M, English K, Hood LJ, Tillery KL, eds. Handbook of clinical audiology. 7th ed. Philadelpia : Wolters Kluwer Health; 2015. p. 29-47.
  5. Kumar D, Singh SP, Thakur VK. Audiologic monitoring of multidrug resistant tuberculosis patient on aminoglycoside treatment with long term follow up. IOSR JDMS. 2017; 16(10):10-15.
  6. Reavis, Phillips KM, Austin G, Gallun D, Fausti F, Gordon SA, et al. Distortion product otoacoustic emission test performance for ototoxicity monitoring. Ear Hear. 2011; 32:61-74.
  7. Rakhmawati L, Agustian RA, Wijana. Peluang kejadian ototoksisitas pada penggunaan kanamisin dalam pengobatan tuberkulosis resisten obat ganda selama satu bulan. MKB. 2015; 47(4):224-30.
  8. Magdalena S, Harsini, Reviono, Aphridasari J, Eko V. Relationship between kanamycin injection treatment and evaluation of hearing loss in multidrugs resistant tuberculosis patients in dr. moewardi hospital. 2013 (cited 2018 Oct 20). Available from http://pulmonologi.fk.uns.ac.id.
  9. Yulianti, Mahdiani S. Gangguan pendengaran penderita tuberkulosis multidrug resistant. Orli. 2015; 45(2):83-89.
  10. Azwar GA, Noviana DI, Hendriyono FX. Karakteristik penderita tuberkulosis paru dengan multidrugs reisitant tuberculosis di rsud ulin Banjarmasin. Berkala Kedokteran. 2017; 13(1):23-32.
  11. Mokrian H, Shaibanizadeh A, Farahani S, Jalaie S, Mahdi P, Amali A, Nahad HA. Evaluation of distortion and transient evoked otoacoustic emission in tinnitus patients with normal hearing. Iranian Journal of Otorhinolaryngology. 2014; 26(1):19-24.
  12. Peloquin CA, Berning SE, Nitta AT. Aminoglycoside toxicity : daily versus weekly dosing for treatment of mycobacterial disease. CID. 2004; 38(6):1538-44.
  13. Urbancic K, Grayson ML. Kanamycin. In : Grayson ML, Cosgrove SE, Crowe S, eds. Kucer's the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs. 6th ed. Melbourne: CRC Press, 2017. p. 1989-2007.
  14. Chang KW. Ototoxicity. In : Jhonson JT, Rosen CA, eds. Bailey's head and neck surgery otolaryngology. 4th ed. Vol 2. Philadephia : Lippincot Williams and Wilkins, 2014. p. 2242-55.
  15. Appana D, Joseph L, Paken J. An audological profile of patients infected with multidrug resistant tuberculosis at a district hospital in kwazulu natal. South African Journal of Communication Disorders. 2016; 63(1):1-12.
  16. Kavalieratos A. Hearing function in adults with multidrugs resistant tuberculosis: a retrospective study. Dissertation. Johanessburg: Degree of Master University of Witwaterstrand; 2012. P.76-99.
  17. Irwan AG, Memy YD, Ahmad Z, Bahar E, Septiany C. Corelation between the length of kanamycin therapy and hearing threshold shift in multidrug resistant tuberculosis (MDR-TB) patients. Journal of Research in Medical and Dental Science. 2017; 5(6):113-8.
  18. Sharma V, Bhagat S, Verma B, Singh R, Singh S. Audiological evaluation of patientstaking kanamycin for multidrug resistant tuberculosis. Iranian Journal of Otorhinolaryngology. 2016; 28(86):203-8.
  19. Seddon JA, Faussett PG, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in patients on treatment for drug resistant tuberculosis. ERJ Express. 2012; 14:1-22.